Hospital Maintenance Rules and After-Sales Obligations for Device Suppliers

1. Key takeaways

The maintenance rule binds medical facilities (healthcare institutions), not manufacturers — but it directly shapes your customers’ procurement behaviour and after-sales requirements. Permenkes No. 15/2023 requires independent medical facilities to carry out preventive and corrective maintenance of devices, invest at least 4% of device asset value annually, keep records, and report every six months.

• For device suppliers, three consequences follow. ① After-sales is a market-access condition — imaging, IVD, surgical, ICU/operating-room and dental equipment all require installation, calibration, maintenance, spare parts and clinical application support, so service capability is itself competitiveness; ② spare parts imports have a dedicated channel — the spare parts import explanation letter (IDR 250,000, 3 working days, validity tied to the marketing authorisation expiry date, one application per marketing authorisation); ③ traceability is a hard requirement — the integration of KFA codes with SATUSEHAT raises the hospital side’s demands for the accuracy of product data.
• The linkage with CDAKB traceability. CDAKB requires distributors to be able to track where products flow, to support authenticity verification and anti-adulteration, and to function during recalls. Hospital maintenance records and distributor traceability records together form a complete chain running from the hospital back to the importer.
• The procurement-side threshold. Government procurement looks at three things: NIE (marketing authorisation) + KFA code + TKDN/BMP local content, and increasingly also weighs price, continuity of supply, catalogue-access compliance and local service capability. Holding a registration approval alone is not enough to generate government sales.
• Permenkes 5/2026 adds a supply-chain obligation. Article 40 requires production facilities, distributors and drug management facilities to maintain a buffer stock of 10%-30% of planned demand, and to report anticipated shortages to the government 6 months in advance. This is a new supply-chain resilience obligation that will affect inventory and capital planning.

2. Legal basis

The facility-side duty comes from Permenkes No. 15/2023: independent medical facilities must perform preventive and corrective maintenance on devices, commit at least 4% of device asset value per year to it, keep the records and submit reports every six months. The supply-chain duty comes from Permenkes No. 5/2026, Article 40, which obliges production facilities, distributors and drug management facilities to hold a buffer stock of 10%-30% of planned demand and to warn the government of anticipated shortages six months ahead. The traceability duty comes from Permenkes No. 4/2014 (CDAKB), which requires distributors to track product flow in support of authenticity verification, anti-adulteration and recalls. The import mechanics come from the Kemenkes Certificate Services Manual, which records the spare parts import explanation letter entry: IDR 250,000, 3 working days, validity linked to the marketing authorisation expiry date, one application per marketing authorisation. Finally, the KFA/SATUSEHAT integration requirements set the data-accuracy expectations that hospitals now apply to their suppliers.

3. Expert insights

The rule regulates your customer, but it prices your product. Because hospitals must spend at least 4% of device asset value annually on maintenance and report every six months, their purchasing decisions internalise lifecycle cost, not just purchase price. A supplier whose equipment is hard to maintain, whose spare parts arrive slowly or whose application support is thin is importing cost into a hospital’s mandatory maintenance budget — and hospital procurement teams understand this arithmetic well. The regulation is therefore best read by manufacturers as a demand-side filter: it converts after-sales capability from a commercial bonus into a procurement qualification factor.

The spare parts import letter is the operational hinge of the after-sales promise. Its parameters — IDR 250,000, 3 working days, validity tied to the marketing authorisation expiry date and one application per marketing authorisation — mean that a supplier’s ability to service installed equipment depends on keeping this instrument alive for every licence it supports. If the letter lapses with the licence, the servicing channel lapses with it. Companies should manage the letter as part of the certificate lifecycle rather than as a transaction document requested ad hoc by a hospital.

The traceability chain now runs door to door. CDAKB requires distributors to track product flow for authenticity verification, anti-adulteration and recalls, while the KFA/SATUSEHAT integration makes hospitals demand accurate product data at the point of use. The hospital’s maintenance records and the distributor’s traceability records close the loop from hospital back to importer. Article 40 of Permenkes 5/2026 extends the same logic upstream, obliging distributors and production facilities to hold 10%-30% buffer stock and to report anticipated shortages six months ahead. Together these rules mean a supplier’s supply-chain data quality is now inspected end to end, not just at the registration stage.

4. Practical recommendations

• Put the maintenance plan, spare parts supply capability and local engineers into every public-hospital bid. Bid on service, not only on price — Indonesian hospitals weigh after-sales response heavily because maintenance is their statutory assessment item.
• Manage the spare parts import explanation letter inside the licence lifecycle. Track its validity against each marketing authorisation expiry date and re-apply on schedule, so the servicing channel never has a gap.
• Build the service package by equipment class. Installation, calibration, maintenance, spare parts and clinical application support should be scoped explicitly for imaging, IVD, surgical, ICU/operating-room and dental equipment.
• Prepare for government procurement as a three-part qualification. NIE, KFA code and TKDN/BMP local content must all be in place, with catalogue-access compliance and supply continuity documented alongside.
• Plan inventory against the Article 40 buffer requirement. Size stock at 10%-30% of planned demand and set a six-month early-warning process for anticipated shortages, folding both into capital planning.

5. Verification checklist

• □ Permenkes No. 15/2023 confirmed: facility maintenance duty, 4% annual budget, semi-annual reporting (verified 26 October 2026)
• □ Permenkes No. 5/2026, Article 40 confirmed: buffer stock 10%-30%, six-month advance shortage warning
• □ Permenkes No. 4/2014 confirmed: CDAKB traceability requirements
• □ Kemenkes Certificate Services Manual confirmed: spare parts import explanation letter entry
• □ KFA/SATUSEHAT integration requirements mapped to product data quality
• □ Bid templates updated with maintenance plan, spare parts capability and local engineers

How GRZAN can help. GRZAN provides medical device and IVD registration, quality system, authorised representative and local testing support across Southeast Asia, including Indonesia. Our team prepares dossiers to ASEAN CSDT structure, manages AKL/AKL-I submissions with Kemenkes, and supports post-market vigilance obligations. Business enquiries: info@grzanglobal.com